This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While this report hit the virtual bookshelf about six months ago, I am revisiting it on this first day of the second quarter of 2025 because of its salience in this moment of uncertainties across our professional and personal lives — particularly related to health politics, global economics and trade, and the erosion of trust in institutions.
This was not the case five years later, Edelman learned earlier this year in the 2025 update : in this year’s mood seen as a Crisis of Grievance, most people were looking for compassion as a place of influence — not a formal position of power.
How will we know if the lifesciences sector is advancing in 2025? This is the question asked at the start of the report, a Research Brief: 2025 Indicators of Progress for the LifeSciences Sector, from the IQVIA Institute for Human Data Science (IQVIA). We start with the state of trust held by U.S.
In the landscape of health care, then, we are concerned about tariffs’ impacts on the costs and supply chains of clinical supplies and equipment, stuff we spend capital and operational dollars on which include a portfolio of things from disposable supplies to pacemakers and digital imaging equipment, along with raw ingredients for medicines.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content